Market Segmentation:
- By Drug Class
- Cholinesterase inhibitors
- NMDA receptor antagonists
- Monoclonal antibodies
- Others
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Stage of Disease
- Mild Alzheimer's
- Moderate Alzheimer's
- Severe Alzheimer's
- By End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of Alzheimer's disease in 2023 is US$ 31.5 billion.
Rising prevalence due to aging populations, Advances in diagnostics and imaging, Emerging pipeline disease-modifying therapies
High drug development costs, low success rates in trials, reimbursement challenges, stigma associated with Alzheimer's, lack of validated biomarkers, misdiagnosis, side effects of drugs, poor adherence, long regulatory timelines, ethical concerns, and alternate treatment preferences
The leading component segment in the Alzheimer’s Disease Market is the cholinesterase inhibitors (used to improve cognition and memory)
Biogen, Eli Lilly, Roche, Novartis, Pfizer, Merck & Co., AstraZeneca, Johnson & Johnson, AbbVie, Amgen
The Alzheimer’s disease market is projected to grow at a CAGR of 8% from US$ 31.5 billion in 2023 to US$ 54 billion by 2030
The key drivers are rising prevalence due to aging populations, advances in diagnostics and imaging techniques, emerging pipeline disease-modifying therapies, increased R&D investments, growing public awareness, government funding for Alzheimer’s care, and favorable regulatory initiatives.